Intermittent dosing of alendronate

Annals of Pharmacotherapy

Volumn 35, Issue 11, 2001, Pages 1471-1475

  Tsun, E C ^a   Heck, A M ^a  

^a WISHARD HEALTH SERVICES   (United States)

Author keywords

Alendronate; Compliance; Dosing; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; FLUORIDE; HORMONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG MARKETING; DRUG TOLERABILITY; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0034764797     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10393     Document Type: Article

References (21)

1. Osteoporosis and osteomalacia
2. An overview of the National Osteoporosis Foundation clinical practice guide
3. Osteoporosis prevention, detection, and treatment: A mandate for primary care physicians
4. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
5. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
6. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
7. Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis
8. Weekly administration of alendronate: Rationale and plan for clinical assessment
9. The effects of 2-year treatment with aminobisphosphonates alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
10. Pharmacokinetics of alendronate
11. Therapeutic equivalence of alendronate 70-mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
12. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis
13. Therapeutic equivalence of alendronate 35 mg once weekly and 5 mg daily in the prevention of postmenopausal osteoporosis
14. A simplified therapeutic scheme of alendronate for postmenopausal osteoporosis
15. Effects of alendronate on biochemical markers of bone turnover in osteoporotic women receiving or not receiving hormone therapy
16. Success of alternative dosing regimens for alendronate intolerance in osteoporosis
17. Upper gastrointestinal toxicity of alendronate
18. Alendronate-associated esophageal injury: Pathologic and endoscopic features
19. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
20. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis